SynthesisScientific reports2016
Risk of malignancy in ankylosing spondylitis: a systematic review and meta-analysis.
Synthesis in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Guideline
- Tubal ligation and endometrial Cancer risk: a global systematic review and meta-analysis.BMC cancer · 2019Pooled it
- Cyclooxygenase-2 selective inhibitors in cancer prevention and therapy: inflammopharmacological basis and translational prospects.Medical oncology (Northwood, London, England) · 2026Review
- Genetic architecture of multiple myeloma: From somatic alterations to germline susceptibility and clinical implications.Translational oncology · 2026Review
- Age-Specific Risk Factors for Cancer in a Long-Term Korean Cohort of Patients with Ankylosing Spondylitis Treated with TNF Inhibitors.Journal of clinical medicine · 2025Article
- Article
- Spondyloarthritis and Risk of Malignancy: A Narrative Review on a Still Controversial Issue.Rheumatology and therapy · 2025Review
- Large-scale genome-wide association studies reveal the genetic causal etiology between ankylosing spondylitis and risk of leukemia and lymphocytic malignancies.Frontiers in oncology · 2024Article
- Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors.Drug safety · 2023Review
- Increased oxidative and chromosomal DNA damage in patients with ankylosing spondylitis: its role in pathogenesis.Clinical and experimental medicine · 2023Article
- The Risk and Predictors of Malignancies in Ankylosing Spondylitis Patients in Israel-A Retrospective Electronic Data-Based Study.Journal of clinical medicine · 2023Article
- Diffuse large B-cell lymphoma presenting as sternal mass in a patient with ankylosing spondylitis: a case report study.Annals of medicine and surgery (2012) · 2023Article
- Malignancy in ankylosing spondylitis: a cross-sectional analysis of a large population database.BMC rheumatology · 2022Article
- Intestinal Peripheral T-Cell Lymphoma in a Patient with Ankylosing Spondylitis Under Treatment with Infliximab: A Case Report and Review of the Literature.Mediterranean journal of rheumatology · 2022Article
- Ankylosing Spondylitis and the Risk of Lung Cancer: A Meta-Analysis and Mendelian Randomization.Frontiers in genetics · 2022Article
- Risk of Malignancy and Biologic Therapy in Rheumatic Inflammatory Diseases: A Single-center Experience.Rheumatology and immunology research · 2020Article
- Article
- Down-regulated miR-495 can target programmed cell death 10 in ankylosing spondylitis.Molecular medicine (Cambridge, Mass.) · 2020Article
- Membranous nephropathy and thymoma in a patient with ankylosing spondylitis: A case report.Medicine · 2020Article
- Rheumatological Findings in Patients with Breast Cancer.European journal of breast health · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current knowledge about the overall and site-specific risk of malignancy associated with ankylosing spondylitis (AS) is inconsistent. We conducted a systematic review and meta-analysis to address this knowledge gap. Five databases (PubMed, EMBASE, Web of Science, the Cochrane library and the virtual health library) were systematically searched. A manual search of publications within the last 2 years in key journals in the field (Annals of the Rheumatic Diseases, Rheumatology and Arthritis &rheumatology) was also performed. STATA 11.2 software was used to conduct the meta-analysis. After screening, twenty-three studies, of different designs, were eligible for meta-analysis. AS is associated with a 14% (pooled RR 1.14; 95% CI 1.03-1.25) increase in the overall risk for malignancy. Compared to controls, patients with AS are at a specific increased risk for malignancy of the digestive system (pooled RR 1.20; 95% CI 1.01 to 1.42), multiple myelomas (pooled RR 1.92; 95% CI 1.37 to 3.69) and lymphomas (pooled RR 1.32; 95% CI 1.11 to 1.57). On subgroup analysis, evidence from high quality cohort studies indicated that AS patients from Asia are at highest risk for malignancy overall. Confirmation of findings from large-scale longitudinal studies is needed to identify specific risk factors and to evaluate treatment effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.